tetano
Editor, Senior Moderator
Nat Commun
. 2022 Apr 4;13(1):1788.
doi: 10.1038/s41467-022-29477-0.
Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
Xiaoqi Yu[SUP] #[/SUP][SUP] 1 [/SUP], Dong Wei[SUP] #[/SUP][SUP] 1 [/SUP], Wenxin Xu[SUP] #[/SUP][SUP] 1 [/SUP], Chuanmiao Liu[SUP] #[/SUP][SUP] 2 [/SUP], Wentian Guo[SUP] 3 [/SUP], Xinxin Li[SUP] 1 [/SUP], Wei Tan[SUP] 1 [/SUP], Leshan Liu[SUP] 3 [/SUP], Xinxin Zhang[SUP] 4 5 [/SUP], Jieming Qu[SUP] 6 7 8 [/SUP], Zhitao Yang[SUP] 9 [/SUP], Erzhen Chen[SUP] 10 [/SUP]
Affiliations
Abstract
The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the generation of variants that may diminish host immune responses to vaccine formulations. Here we show a registered observational clinical trial (NCT04795414), we assess the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine BBIBP-CorV in a cohort of 1006 vaccine recipients. No serious adverse events are observed during the term of the study. Detectable virus-specific antibody is measured and determined to be neutralizing in 698/760 (91.84%) vaccine recipients on day 28 post second vaccine dose and in 220/581 (37.87%) vaccine recipients on day 180 post second vaccine dose, whereas vaccine-elicited sera show varying degrees of reduction in neutralization against a range of key SARS-CoV-2 variants, including variant Alpha, Beta, Gamma, Iota, and Delta. Our work show diminished neutralization potency against multiple variants in vaccine-elicited sera, which indicates the potential need for additional boost vaccinations.
. 2022 Apr 4;13(1):1788.
doi: 10.1038/s41467-022-29477-0.
Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
Xiaoqi Yu[SUP] #[/SUP][SUP] 1 [/SUP], Dong Wei[SUP] #[/SUP][SUP] 1 [/SUP], Wenxin Xu[SUP] #[/SUP][SUP] 1 [/SUP], Chuanmiao Liu[SUP] #[/SUP][SUP] 2 [/SUP], Wentian Guo[SUP] 3 [/SUP], Xinxin Li[SUP] 1 [/SUP], Wei Tan[SUP] 1 [/SUP], Leshan Liu[SUP] 3 [/SUP], Xinxin Zhang[SUP] 4 5 [/SUP], Jieming Qu[SUP] 6 7 8 [/SUP], Zhitao Yang[SUP] 9 [/SUP], Erzhen Chen[SUP] 10 [/SUP]
Affiliations
- PMID: 35379815
- DOI: 10.1038/s41467-022-29477-0
Abstract
The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the generation of variants that may diminish host immune responses to vaccine formulations. Here we show a registered observational clinical trial (NCT04795414), we assess the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine BBIBP-CorV in a cohort of 1006 vaccine recipients. No serious adverse events are observed during the term of the study. Detectable virus-specific antibody is measured and determined to be neutralizing in 698/760 (91.84%) vaccine recipients on day 28 post second vaccine dose and in 220/581 (37.87%) vaccine recipients on day 180 post second vaccine dose, whereas vaccine-elicited sera show varying degrees of reduction in neutralization against a range of key SARS-CoV-2 variants, including variant Alpha, Beta, Gamma, Iota, and Delta. Our work show diminished neutralization potency against multiple variants in vaccine-elicited sera, which indicates the potential need for additional boost vaccinations.